Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

340 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to Evaluate the Efficacy and Safety of Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.

NCT00377078

Clostridium Difficile

UNKNOWN NA

A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years

NCT02561195

Clostridium Difficile Associated Disease

COMPLETED PHASE2

Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701

NCT03576183

Enterotoxigenic Escherichia Coli Infection Diarrhea

COMPLETED PHASE2

Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli

NCT02541695

Diarrhea Gastroenteritis Bacterial Infections +1 more

COMPLETED NA

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

NCT00075868

Anal Cancer Colorectal Cancer Drug/Agent Toxicity by Tissue/Organ +1 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diarrhea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ven100

Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients

Group Type EXPERIMENTAL

Lactoferrin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lactoferrin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female patients 50 years of age and older.
2. Resident of a participating long term care facility.
3. Able to consume 30 mL of liquid solution two time per day by mouth or enteral feeding tube.
4. Patient has had no antibiotics in the 4 weeks preceding enrollment in the study.
5. Patient has been started on a broad spectrum antibiotic(s) for an infection other than gastroenteritis.
6. Patient has a life expectancy greater than 6 months.
7. Patient or health care agent is able and willing to sign a written informed consent.
8. Patient or caregiver is able and willing to complete diary of daily bowel movement information (number, formed or unformed, time) during any portion of the 8 week study.

Exclusion Criteria

1. Patient has an ileostomy.
2. Patient has a prior history of major gastrointestinal surgery such as partial small bowel or colon resection or gastric bypass.
3. Patient has a history of inflammatory bowel disease.
4. Patient has a history of chronic diarrhea associated with irritable bowel syndrome or other etiologies.
5. Patient has a history of severe constipation requiring use of enemas or disimpaction within 30 days prior to enrollment.
6. Patient has signs or symptoms of C. difficile infection including diarrhea.
7. Patient has signs or symptoms of acute or chronic diarrhea.
8. Patient has known sensitivity or allergy to rice or rice products.
9. Patient has significant medical problems which in the judgment of the principal investigator or medical monitor may interfere with participation in the study.
10. Patient is not receiving an antibiotic regimen consisting of a broad spectrum antibiotic.
11. Patient has participated in an investigational study using an investigational product within 30 days of randomization.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No